Van Eck Associates Corp Novo Cure LTD Transaction History
Van Eck Associates Corp
- $78.1 Billion
- Q4 2024
A detailed history of Van Eck Associates Corp transactions in Novo Cure LTD stock. As of the latest transaction made, Van Eck Associates Corp holds 21,059 shares of NVCR stock, worth $407,702. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,059
Previous 24,244
13.14%
Holding current value
$407,702
Previous $392,000
60.2%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding NVCR
# of Institutions
290Shares Held
75.6MCall Options Held
1.77MPut Options Held
538K-
Black Rock Inc. New York, NY12.1MShares$235 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$228 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$172 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$93.2 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.74MShares$53 Million5.68% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.03B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...